Athira Pharma Announces 2024 Annual Meeting of Stockholders
Ticker: LONA · Form: DEF 14A · Filed: Apr 9, 2024 · CIK: 1620463
| Field | Detail |
|---|---|
| Company | Athira Pharma, INC. (LONA) |
| Form Type | DEF 14A |
| Filed Date | Apr 9, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Athira Pharma, DEF 14A, Annual Meeting, Proxy Statement, Stockholder Vote
TL;DR
<b>Athira Pharma invites stockholders to its virtual 2024 Annual Meeting on May 23, 2024, urging prompt proxy submission.</b>
AI Summary
Athira Pharma, Inc. (LONA) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. Athira Pharma, Inc. will hold its 2024 Annual Meeting of Stockholders on May 23, 2024, at 8:00 a.m. Pacific Time. The meeting will be conducted virtually via live audio webcast at www.virtualshareholdermeeting.com/ATHA2024. Stockholders can listen to the meeting, submit questions, and vote online. The company urges stockholders to vote and submit their proxy promptly via internet, telephone, or mail. Mark J. Litton, Ph.D., President and Chief Executive Officer, signed the proxy statement.
Why It Matters
For investors and stakeholders tracking Athira Pharma, Inc., this filing contains several important signals. This filing is a Definitive Proxy Statement (DEF 14A), indicating it contains important information for shareholders regarding the upcoming annual meeting and voting procedures. The virtual format of the meeting aims to increase accessibility for stockholders to participate, ask questions, and cast their votes.
Risk Assessment
Risk Level: low — Athira Pharma, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational disclosures that would indicate significant risk.
Analyst Insight
Stockholders should review the proxy statement for details on proposals and vote their shares to ensure their voice is heard at the annual meeting.
Key Numbers
- 2024 — Annual Meeting Year (Athira Pharma's 2024 Annual Meeting of Stockholders.)
- May 23 — Meeting Date (Date of the 2024 Annual Meeting.)
- 8:00 a.m. PT — Meeting Time (Time of the 2024 Annual Meeting.)
Key Players & Entities
- Athira Pharma, Inc. (company) — Registrant and filer of the proxy statement.
- Mark J. Litton, Ph.D. (person) — President and Chief Executive Officer of Athira Pharma, Inc.
- 2024 (date) — Year of the Annual Meeting.
- May 23, 2024 (date) — Date of the Annual Meeting.
- 8:00 a.m., Pacific Time (time) — Time of the Annual Meeting.
- www.virtualshareholdermeeting.com/ATHA2024 (url) — Web address for the virtual annual meeting.
FAQ
When did Athira Pharma, Inc. file this DEF 14A?
Athira Pharma, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 9, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Athira Pharma, Inc. (LONA).
Where can I read the original DEF 14A filing from Athira Pharma, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Athira Pharma, Inc..
What are the key takeaways from Athira Pharma, Inc.'s DEF 14A?
Athira Pharma, Inc. filed this DEF 14A on April 9, 2024. Key takeaways: Athira Pharma, Inc. will hold its 2024 Annual Meeting of Stockholders on May 23, 2024, at 8:00 a.m. Pacific Time.. The meeting will be conducted virtually via live audio webcast at www.virtualshareholdermeeting.com/ATHA2024.. Stockholders can listen to the meeting, submit questions, and vote online..
Is Athira Pharma, Inc. a risky investment based on this filing?
Based on this DEF 14A, Athira Pharma, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational disclosures that would indicate significant risk.
What should investors do after reading Athira Pharma, Inc.'s DEF 14A?
Stockholders should review the proxy statement for details on proposals and vote their shares to ensure their voice is heard at the annual meeting. The overall sentiment from this filing is neutral.
How does Athira Pharma, Inc. compare to its industry peers?
Athira Pharma operates in the biotechnology sector, focusing on developing therapies for neurodegenerative diseases.
Are there regulatory concerns for Athira Pharma, Inc.?
This filing is made under the Securities Exchange Act of 1934, specifically Rule 14A-101, which governs the content of proxy statements.
Industry Context
Athira Pharma operates in the biotechnology sector, focusing on developing therapies for neurodegenerative diseases.
Regulatory Implications
This filing is made under the Securities Exchange Act of 1934, specifically Rule 14A-101, which governs the content of proxy statements.
What Investors Should Do
- Review the proxy statement for details on proposals to be voted on at the annual meeting.
- Submit your proxy vote via internet, telephone, or mail before the meeting date.
- Attend the virtual annual meeting on May 23, 2024, to listen, ask questions, and vote online.
Key Dates
- 2024-05-23: Annual Meeting of Stockholders — Key date for stockholders to participate and vote.
- 2024-04-09: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Year-Over-Year Comparison
This is a DEF 14A filing for the 2024 annual meeting, following the typical schedule for such corporate events.
Filing Stats: 4,589 words · 18 min read · ~15 pages · Grade level 12 · Accepted 2024-04-09 08:32:24
Filing Documents
- ny20019772x2_def14a.htm (DEF 14A) — 843KB
- logo_athirapharma.jpg (GRAPHIC) — 30KB
- ny20019772x2-pc_1x1.jpg (GRAPHIC) — 654KB
- ny20019772x2-pc_2x1.jpg (GRAPHIC) — 568KB
- ny20019772x2_agengos.jpg (GRAPHIC) — 29KB
- ny20019772x2_barbkosacz.jpg (GRAPHIC) — 29KB
- ny20019772x2_cover.jpg (GRAPHIC) — 297KB
- ny20019772x2_date.jpg (GRAPHIC) — 9KB
- ny20019772x2_gpickering.jpg (GRAPHIC) — 27KB
- ny20019772x2_icon1.jpg (GRAPHIC) — 9KB
- ny20019772x2_jajohnson.jpg (GRAPHIC) — 25KB
- ny20019772x2_jedelman.jpg (GRAPHIC) — 25KB
- ny20019772x2_jmfluke2.jpg (GRAPHIC) — 26KB
- ny20019772x2_karomano.jpg (GRAPHIC) — 29KB
- ny20019772x2_kchurch.jpg (GRAPHIC) — 27KB
- ny20019772x2_location.jpg (GRAPHIC) — 8KB
- ny20019772x2_mail.jpg (GRAPHIC) — 7KB
- ny20019772x2_mlitton.jpg (GRAPHIC) — 26KB
- ny20019772x2_mpanzara.jpg (GRAPHIC) — 25KB
- ny20019772x2_mworthington.jpg (GRAPHIC) — 27KB
- ny20019772x2_online.jpg (GRAPHIC) — 10KB
- ny20019772x2_phone.jpg (GRAPHIC) — 7KB
- ny20019772x2_record.jpg (GRAPHIC) — 9KB
- ny20019772x2_rlenington.jpg (GRAPHIC) — 30KB
- ny20019772x2_time.jpg (GRAPHIC) — 10KB
- ny20019772x2_virtual.jpg (GRAPHIC) — 8KB
- sig_mjlitton.jpg (GRAPHIC) — 12KB
- 0001140361-24-018750.txt ( ) — 3544KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 34 Processes and Procedures for Compensation Decisions ​ ​ 34
Executive Compensation
Executive Compensation ​ ​ 34 2022-2023 Summary Compensation Table ​ ​ 35 Outstanding Equity Awards at December 31, 2023 ​ ​ 36 Executive Employment Arrangements ​ ​ 37 Change in Control and Severance Agreements ​ ​ 38 Equity Incentive Plans ​ ​ 41 Clawback Policy ​ ​ 41 Executive Incentive Compensation Plan ​ ​ 41
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ​ ​ 43 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS ​ ​ 45 RELATED PERSON TRANSACTIONS ​ ​ 46 Related-Person Transactions Policy ​ ​ 46 Investors’ Rights Agreement ​ ​ 46 Other Transactions ​ ​ 47 OTHER MATTERS ​ ​ 48 Availability of Bylaws ​ ​ 48 2023 Annual Report ​ ​ 48 ANNEX A ​ ​ 49 TABLE OF CONTENTS   FOR 2024 ANNUAL MEETING Proxy Statement Summary Meeting Date: May 23, 2024 Meeting Time: 8:00 a.m., Pacific Time Meeting Location: The Annual Meeting will be conducted virtually via live audio webcast. You will be able to attend the Annual Meeting virtually by visiting www. virtualshareholder meeting.com/ ATHA2024, where you will be able to listen to the meeting live, submit questions and vote online during the meeting. VOTING MATTERS Proposal ​ ​ ​ ​ Board Recommendation ​ ​ Page Reference 1 ​ ​ To elect three Class I directors of the Company, each to serve for a term of three years and until his or her respective successor is elected and qualified, or until his or her earlier death, resignation or removal. ​ ​ “FOR” the election of each Class I director nominee named ​ ​ 25 2 ​ ​ To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2024. ​ ​ “FOR” the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024 ​ ​ 26 3 ​ ​ To approve an amendment to the Company’s amended and restated